斑秃是一种以斑块状脱发为特征的自身免疫性疾病，这种脱发通常发生在头皮上，但也会影响眉毛、睫毛、面部毛发和身体的其他部位。斑秃患者的症状由免疫细胞攻击健康毛囊引起，导致头发脱落。斑秃平均发病年龄在25至35岁之间，但也可影响老年人、儿童和青少年，无明显性别差异。斑秃严重影响患者健康和生活质量，可能引起严重心理障碍，包括抑郁和焦虑。据估计，美国约有680万人患有斑秃，全球约有1.47亿人患有斑秃。 利 ...

JAK inhibitors like baricitinib, ritlecitinib, and brepocitinib show promise in treating alopecia areata, with baricitinib ...

Given as a once-daily tablet, Litfulo (ritlecitinib) has been recommended by cost-effectiveness agency NICE for use in people aged 12 and over. The decision comes a few months after the first drug ...

Treatment with ritlecitinib sustained hair regrowth through week 48 in patients with alopecia areata (AA), and up to one third of nonresponders at week 24 also achieved responses by week 48.

The daily pill, called ritlecitinib or Litfulo, was green-lit for prescription on the NHS in February and is thought to grow ...

Eli Lilly and Incyte have another rival in the rear-view mirror for Olumiant in alopecia areata after Pfizer reported that its ritlecitinib improved scalp hair regrowth in a late-stage trial.

Ritlecitinib, provided under the brand name Litfulo, had previously been approved in England. It is for treating severe alopecia areata in people who are aged 12 and over. Last month Megan ...

Called Ritlecitinib or Litfulo, it could help thousands of people dealing with severe hair loss or alopecia. The Welsh government has confirmed the drug will be available in Wales. First Dates ...